On Nov. 21, 2016, Novartis announced it had acquired Selexys Pharmaceuticals Corp, a Oklahoma City-based company that specialized in development of therapeutics in certain hematologic and inflammatory disorders.

Novartis obtained the exclusive right to acquire Selexys and SelG1 in 2012. Terms of the deal totaled up to $665 million in upfront, acquisition and milestone payments.